Assembly Biosciences (NASDAQ:ASMB) versus Parnell Pharmaceuticals (OTCMKTS:PARNF) Head-To-Head Review

Assembly Biosciences (NASDAQ:ASMB) and Parnell Pharmaceuticals (OTCMKTS:PARNF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Profitability

This table compares Assembly Biosciences and Parnell Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-103.65%	-59.01%	-28.61%
Parnell Pharmaceuticals	N/A	N/A	N/A

Earnings and Valuation

This table compares Assembly Biosciences and Parnell Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$28.52 million	14.87	-$40.18 million	($4.79)	-5.59
Parnell Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Parnell Pharmaceuticals has lower revenue, but higher earnings than Assembly Biosciences.

Institutional & Insider Ownership

19.9% of Assembly Biosciences shares are held by institutional investors. 5.1% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Assembly Biosciences and Parnell Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1	1	6	0	2.63
Parnell Pharmaceuticals	0	0	0	0	0.00

Assembly Biosciences currently has a consensus price target of $41.00, indicating a potential upside of 52.99%. Given Assembly Biosciences’ stronger consensus rating and higher probable upside, analysts clearly believe Assembly Biosciences is more favorable than Parnell Pharmaceuticals.

Summary

Assembly Biosciences beats Parnell Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Assembly Biosciences

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

About Parnell Pharmaceuticals

Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal – U.S., Production Animal – Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.